NEJM Interview: Dr. Roy Perlis on esketamine as an option for treatment-resistant depression. - podcast episode cover

NEJM Interview: Dr. Roy Perlis on esketamine as an option for treatment-resistant depression.

Jul 03, 20198 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Dr. Roy Perlis is the director of the Center for Quantitative Health at Massachusetts General Hospital and a professor of psychiatry at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J. Kim and Others. Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class. N Engl J Med 2019;381:1-4.
For the best experience, listen in Metacast app for iOS or Android